IDH-mutant oligodendroglioma

Last update 23 Jan 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with IDH-mutant oligodendroglioma

Vorasidenib

Target

IDH1 x IDH2

Mechanism

IDH1 inhibitors [+1]

Active Org.

Institut de Recherches Intern Servier [+7]

Originator Org.

Celgene Corp.

Active Indication

Diffuse Astrocytoma [+14]

Inactive Indication

Acute Myeloid Leukemia [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Aug 2024

100 Clinical Results associated with IDH-mutant oligodendroglioma

100 Translational Medicine associated with IDH-mutant oligodendroglioma

0 Patents (Medical) associated with IDH-mutant oligodendroglioma

Literatures (Medical) associated with IDH-mutant oligodendroglioma

06 Jan 2025·Current Computer-Aided Drug Design

Identification of a ceRNA Network Regulating Malignant Transformation of Isocitrate Dehydrogenase Mutant Astrocytoma: An Integrated Bioinformatics Study

Article

Author: Shen, Mingxue ; Zheng, Hongquan ; Qiu, Runze ; Liu, Suo ; Li, Yingbin ; Cui, Yaqian ; Fan, Hongwei ; Zhou, Zhengwei ; Zhang, Xiong

Introduction:Astrocytoma is the most common glioma, accounting for about 65% of glioblastoma. Its malignant transformation is also one of the important causes of patient mortality, making it the most prevalent and difficult to treat in primary brain tumours. However, little is known about the underlying mechanisms of this transformation.Methods:In this study, we established a ceRNA network to screen out the potential regulatory pathways involved in the malignant transformation of IDH-mutant astrocytomas. Firstly, the Chinese Glioma Genome Atlas (CGGA) was employed to compare the expression levels of the differential expressed genes (DEGs) in astrocytomas. Then, the ceRNA-regulated network was constructed based on the interaction of lncRNA-miRNA-mRNA. The Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to explore the main functions of the differentially expressed genes. COX regression analysis and log-rank test were combined to screen the ceRNA network further. In addition, quantitative real-time PCR (qRT-PCR) was conducted to identify the potential regulatory mechanisms of malignant transformation in IDH-mutant astrocytoma. We constructed a ceRNA network with 34 lncRNAs, 29 miRNAs, and 71 mRNAs.Results:GO and KEGG analyses results suggested that DEGs were associated with tumor-associated molecular functions and pathways. In addition, we screened two ceRNA regulatory networks using Cox regression analysis and log-rank test. QRT-PCR assay identified the NAA11/hsa- miR-142-3p/GS1-39E22.2 regulatory axis of the ceRNA network to be associated with the malignant transformation of IDH-mutant astrocytoma.Conclusion:The discovery of this mechanism deepens our understanding of the molecular mechanisms of malignant transformation in astrocytomas and provides new perspectives for exploring glioma progression and targeted therapies.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Who we are

Solutions
Plan
Contact us: phs@patsnap.com

What we do

Drug
Clinical Progress
Patent
Literature
Report
News

IDH-mutant oligodendroglioma

Basic Info

Related

Analysis